TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05378984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: before - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)
Study: NCT03580590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Diltiazem
Description: Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Diltiazem
Description: Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tranexamic Acid
Description: Tranexamic acid inhibits fibrinolysis, which reduces blood loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT03384264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
Study: NCT03669055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
Study: NCT03753919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
Study: NCT03025308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT02525757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: 1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: 1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
Study: NCT03025308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT04152772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
Study: NCT02525757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
Study: NCT04452864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.

Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Cognitive Training
Description: The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Documentaries with delayed Computerized Cognitive Training
Description: The active control group watches documentaries for three months before starting with the CCT.
Study: NCT03518125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: Other Names:~Anthrax Vaccine Adsorbed (AVA)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: Other Names:~Anthrax Vaccine Adsorbed (AVA)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
Study: NCT03098654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood glucose and blood pressure testing
Description: Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle counseling
Description: All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM/HTN medications as needed
Description: Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
Study: NCT04114201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSI
Description: Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
Study: NCT04490603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality experience
Description: Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
Study: NCT00811811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral neurocardiac training
Description: 6 training sessions scheduled over 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic relaxation training
Description: 6 training sessions scheduled over 8 weeks
Study: NCT03745729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol sustained-release capsules
Description: allopurinol sustained-release capsules (0.25g), once a day, one pill at a time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo sustained-release capsules, once a day, one pill at a time
Study: NCT03518125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride injection USP, 0.9% (placebo)
Description: Other Names:~Saline Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride injection USP, 0.9% (placebo)
Description: Other Names:~Saline Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride injection USP, 0.9% (placebo)
Description: Other Names:~Saline Solution
Study: NCT00582946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid
Description: Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
Study: NCT04210414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Transfer of only one embryo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Transfer of only one embryo
Study: NCT00239564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 100 mg
Description: IPX054 containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 150 mg
Description: IPX054 containing 37.5 mg carbidopa and 150 mg levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 200 mg
Description: CD-LD CR containing 50 mg carbidopa and 200 mg levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 250 mg
Description: CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 300 mg
Description: CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
Study: NCT04207840

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.125 mg/inhalation)
Description: Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
Study: NCT02064842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
Study: NCT04207840

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Injection Auto-Injector (0.3mg/0.3mL)
Description: Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate (0.09 mg/inhalation)
Description: Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
Study: NCT02466646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klorhex® Gel, rinse and spray
Description: Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional IPT
Description: Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth IPT
Description: Initial periodontal treatment was performed in 2 sessions within 24 hours.
Study: NCT04604301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Quatro
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Quatro
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Quatro
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Quatro
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
Study: NCT04671238

Intervention type: DEVICE
Intervention: SPECT CT
Description: SPECT/CT scan of the spine as part of a vertebroplasty
Study: NCT01271998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: 200 mg, oral, once daily for 3 days.
Study: NCT04508179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Single Ascending Dose
Description: Part A: 7HP349 Capsules, Single Ascending Dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Multiple Ascending Dose
Description: Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single Ascending Dose
Description: Part A: Placebo Capsules, Single Ascending Dose (SAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple Ascending Dose
Description: Part B: Placebo Capsules, Multiple Ascending Dose (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Food Effect
Description: Part C: 7HP349 Capsules, Food Effect
Study: NCT03611504

Intervention type: DEVICE
Intervention: Hemospray®
Description: Hemospray® application
Study: NCT03585296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-502
Description: Topical Solution
Study: NCT01493505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386
Description: AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 or 6 IV Q3W (6 cycles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
Study: NCT01485991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TVR
Description: TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Study: NCT00915876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: paricalcitol 1 mcg QD x 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Paricalcitol 1 mcg QD x 8 weeks
Study: NCT04312867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project STRONG
Description: Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
Study: NCT00665860

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three pills per day for two years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Three pills that delivered 80 mg of aglycone isoflavones per day for two years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Three pills that delivered 120 mg aglycone isoflavones per day for two years
Study: NCT02658955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short stitch
Description: Surgeons will receive instructions to change the technique of abdominal wall closure
Study: NCT03105479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin capsule
Description: Capsule containing 125 mg of vancomycin to be administered orally 4 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin solution
Description: Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
Study: NCT02626130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT00565643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified sodium hyaluronic acid and carboxymethylcellulose
Description: Adhesion barrier applied at the time of initial cesarean delivery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Routine abdominal closure without placement of adhesion barrier